arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Sarepta Therapeutics, Inc.

SRPT
$16.77 ▼ -0.01 (-0.03%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Sarepta Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.8B
Dividend Yield
Revenue Growth -1.9%
Op. Margin 49.0%
ROIC 14.8%
FCF / Share $-1.95
Trailing P/E 5.3x
Price / Book 1.2x
FCF Yield
Debt / Equity 0.56
info Valuation on last close. End-of-day price, Aug 7, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$730.80M
↓ -1.9%
Net Income Profit after all expenses
$330.96M
↑ +217.0%
Operating Margin Operating profit as % of sales
49.0%
↑ +152.8% 7th
FCF / Share Free cash flow per share
$-1.95
↑ +69.7%
Long-Term Debt Long-term obligations
$838.16M
↑ +496.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
14
Financial Health
52
Cash Quality
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 69 quarters